Literature DB >> 18375892

Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?

René Adam1, Dennis A Wicherts, Robbert J de Haas, Thomas Aloia, Francis Lévi, Bernard Paule, Catherine Guettier, Francis Kunstlinger, Valérie Delvart, Daniel Azoulay, Denis Castaing.   

Abstract

PURPOSE: Complete clinical response (CCR) of colorectal liver metastases (CLM) following chemotherapy is of limited predictive value for complete pathologic response (CPR) and cure of the disease. The objective of this study was to determine predictive factors of CPR as well as its impact on survival. PATIENTS AND METHODS: From January 1985 to July 2006, 767 consecutive patients with CLM underwent liver resection after systemic chemotherapy. Patients with CPR were compared with patients without CPR.
RESULTS: Twenty-nine of 767 (4%) patients had CPR, and none of these 29 patients had CCR. Patients with CPR (mean age, 54 years) had a mean number of 3.3 metastases at diagnosis (mean size, 29.3 mm). Objective response and stable disease were observed in 79% and 21% of cases, respectively. Postoperative mortality rate was 0%. After a median follow-up of 52.2 months (range, 1.1 to 193.0 months), overall 5-year survival was 76% for patients with CPR compared with 45% for patients without CPR (P = .004). Independent predictive factors for CPR were: age <or= 60 years, size of metastases <or= 3 cm at diagnosis, carcinoembryonic antigen (CEA) level at diagnosis <or= 30 ng/mL, and objective response following chemotherapy. The probability of CPR ranged from 0.2% when all factors were absent to 30.9% when all were present.
CONCLUSION: CPR was observed in 4% of patients with CLM treated with preoperative chemotherapy. However, CPR may occur in almost one-third of objective responders age <or= 60 years with metastases <or= 3 cm and low CEA values. CPR is associated with uncommon high survival rates.

Entities:  

Mesh:

Year:  2008        PMID: 18375892     DOI: 10.1200/JCO.2007.13.7471

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  65 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis.

Authors:  Damien Bergeat; Michel Rayar; Yann Mouchel; Aude Merdrignac; Bernard Meunier; Astrid Lièvre; Karim Boudjema; Laurent Sulpice
Journal:  Langenbecks Arch Surg       Date:  2017-01-13       Impact factor: 3.445

3.  Augmented Reality Guidance for the Resection of Missing Colorectal Liver Metastases: An Initial Experience.

Authors:  Dimitrios Ntourakis; Ricardo Memeo; Luc Soler; Jacques Marescaux; Didier Mutter; Patrick Pessaux
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

4.  Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.

Authors:  Filippo Pietrantonio; Pamela Biondani; Alessandro Pellegrinelli; Alfonso Marchianò; Katia Fiorella Dotti; Roberto Buzzoni; Maria Di Bartolomeo
Journal:  Med Oncol       Date:  2012-01-21       Impact factor: 3.064

5.  Surgical management of colorectal liver metastases.

Authors:  Waleed M Mohammad; Fady K Balaa
Journal:  Clin Colon Rectal Surg       Date:  2009-11

Review 6.  Curable metastatic colorectal cancer: recommended paradigms.

Authors:  Richard N Berri; Eddie K Abdalla
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

7.  Predictive value of neoadjuvant chemotherapy for the clinical utility of subsequently performed major cancer surgery.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

8.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Authors:  René Adam; Emir Hoti; Gunnar Folprecht; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2009-09

9.  Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

Authors:  Yun Shin Chun; Jean-Nicolas Vauthey; Piyaporn Boonsirikamchai; Dipen M Maru; Scott Kopetz; Martin Palavecino; Steven A Curley; Eddie K Abdalla; Harmeet Kaur; Chusilp Charnsangavej; Evelyne M Loyer
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

10.  Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.

Authors:  Neal W Wilkinson; Greg Yothers; Samia Lopa; Joseph P Costantino; Nicholas J Petrelli; Norman Wolmark
Journal:  Ann Surg Oncol       Date:  2010-04       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.